BioXcel Therapeutics Inc (BTAI) Director Buys $20,555.91 in Stock

BioXcel Therapeutics Inc (NASDAQ:BTAI) Director Peter Mueller purchased 4,007 shares of the company’s stock in a transaction on Tuesday, December 4th. The shares were bought at an average cost of $5.13 per share, with a total value of $20,555.91. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ:BTAI traded up $0.20 during midday trading on Thursday, reaching $5.06. The company’s stock had a trading volume of 17,000 shares, compared to its average volume of 41,960. BioXcel Therapeutics Inc has a 1 year low of $4.65 and a 1 year high of $14.79.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Friday, November 9th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.05). On average, research analysts anticipate that BioXcel Therapeutics Inc will post -1.12 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of BioXcel Therapeutics in the third quarter valued at $102,000. Point72 Asset Management L.P. grew its position in shares of BioXcel Therapeutics by 10.7% in the second quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after purchasing an additional 6,358 shares during the period. BlackRock Inc. purchased a new stake in shares of BioXcel Therapeutics in the second quarter valued at $137,000. Artemis Investment Management LLP grew its position in shares of BioXcel Therapeutics by 1.3% in the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock valued at $9,700,000 after purchasing an additional 16,358 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of BioXcel Therapeutics in the first quarter valued at $316,000. 20.79% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have weighed in on BTAI shares. Zacks Investment Research raised BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Tuesday, August 14th. Canaccord Genuity reissued a “buy” rating and set a $21.00 price target on shares of BioXcel Therapeutics in a research report on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. BioXcel Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $18.67.

COPYRIGHT VIOLATION NOTICE: “BioXcel Therapeutics Inc (BTAI) Director Buys $20,555.91 in Stock” was posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.wkrb13.com/2018/12/07/bioxcel-therapeutics-inc-btai-director-buys-20555-91-in-stock.html.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: Put Option

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply